IMP [BUY +36.2%] - Sales growth to rebound as COVID-19 disruptions ease - Update
  • 2020-11-09T20:39:10
  • Company Research
We reiterate BUY as we believe IMP’s leading production technology and ample spare capacity along with a favorable policy backdrop that favors high-quality, locally produced drugs in the hospital channel will lead to elevated earnings growth in the next few years.